What is Immuneering?
Immuneering is dedicated to developing and commercializing groundbreaking medicines for a broad spectrum of cancer patients. Its core technology, Deep Cyclic Inhibition, targets the MAPK pathway, a critical signaling cascade implicated in numerous cancers. The company's lead product candidates, IMM-1-104 and IMM-6-415, are both oral inhibitors currently undergoing Phase 1/2a clinical trials. IMM-1-104 is being evaluated in patients with advanced solid tumors harboring RAS mutations, while IMM-6-415 is being tested in patients with advanced solid tumors with either RAS or RAF mutations. The company's robust pipeline also includes several early-stage programs, indicating a sustained commitment to innovation in oncology.
How much funding has Immuneering raised?
Immuneering has raised a total of $219.5M across 4 funding rounds:
Series A
$20M
Series B
$62M
Share Placement
$112.5M
Private Equity
$25M
Series A (2020): $20M with participation from Boxcar PMJ LLC
Series B (2021): $62M led by Rock Springs Capital, BlackRock, LYFE Capital, Surveyor Capital, T. Rowe Price, Cormorant Asset Management, and Perceptive Advisors
Share Placement (2021): $112.5M, investors not publicly disclosed
Private Equity (2025): $25M, investors not publicly disclosed
Key Investors in Immuneering
Rock Springs Capital
Rock Springs Capital is a real estate investment firm with a history of investing and providing brokerage services since 1993, focusing on various asset classes across Texas.
BlackRock
BlackRock is a global investment management firm offering a comprehensive range of investment products and services, managing assets across various classes for institutional and individual investors.
T. Rowe Price
T. Rowe Price Group, founded in 1937, provides investment management services to individuals and institutions, managing equity and fixed income mutual funds globally.
What's next for Immuneering?
With the recent influx of major strategic investment and a history of significant enterprise-level funding, Immuneering is poised for accelerated growth. The company is expected to advance its lead candidates through late-stage clinical trials and expand its pipeline of novel oncology therapeutics. The strategic backing from prominent investors suggests a strong belief in Immuneering's scientific approach and its potential to address significant unmet needs in cancer treatment. Future developments will likely focus on demonstrating clinical efficacy and safety, paving the way for potential regulatory submissions and market entry.
See full Immuneering company page
